Increased risk of infectious disease prevalence are projected to propel the biodefense market forward.

The global biodefense market was worth USD 12.3 billion in 2019 and is predicted to increase at a 5.9% compound annual growth rate (CAGR) from 2020 to 2027. Biodefense is a collection of medical or military procedures done to restore a country's biosecurity against biological poisons or infectious agents that can be used to kill or infect humans, animals, or the environment, as well as to launch biological warfare. Living organisms such as bacteria, viruses, fungi, and poisons can be utilised as bioterrorism agents. These agents can be employed to infect and kill humans in order to cause social and economic chaos.The market for biodefense is being driven by factors such as favourable government initiatives in the United States, growing investment from private players, increased government focus and funding towards biodefense strategies, and the rising prevalence of various agents such as the Ebola Virus, Zika Virus, and Flu.

In the last few decades, advances in genetic engineering and biotechnology have made it easier to manipulate these deadly and naturally existing viruses, which can now be re-engineered to cause much more harm. Furthermore, these organisms are readily available, making biodefense a critical factor for countries all over the world. Anthrax, botulism, chemical and nuclear agents, as well as other biological agents, have all been employed as carriers for bioterrorism in the past, causing considerable economic damage. As a result of these tragedies, the government has enacted biodefense legislation, treaties, and policies to combat biological threats, decrease risks, and prepare for, respond to, and recover from bio-incidents. Since the 2001 anthrax bio-terrorism attack via mail, the National Institute of Infectious Diseases (NIID) has played a critical role in developing medical products and strategies to combat bioterrorism and emerging and re-emerging infectious diseases by conducting ongoing research to diagnose, treat, and prevent them, whether deliberate or naturally occurring.

Many countries' governments have been working with a number of international partners to help response efforts and improve readiness. The World Health Organization and the DRC Ministry of Health, for example, have approved an experimental single-dose Ebola vaccine developed by Merck [rVSV-ZEBOV-GP] for safe use. Approximately 250,000 people at risk for Ebola have been vaccinated as of November 17, 2019. Many companies, such as Bavarian Nordic and Ology Bioservices, are conducting research on Ebola and Zika virus in nations with poor medical infrastructure and research capacity. The Project BioShield Act was introduced as a strategic choice to enhance funding for the procurement, development, and use of medical countermeasures against biological, chemical, radiological, and nuclear (CBRN) warfare agents. The aforementioned considerations, as well as the increased risk of infectious disease prevalence, are projected to propel the biodefense market forward.

The biodefense industry is highly competitive. One of the key drivers of market rivalry is the rapid application of advanced technology in the development of vaccines and pharmaceuticals. Key players are increasingly opting for strategic collaborations with governments in order to obtain bulk purchases and receive strategic collaborations with governments. Many firms are collaborating to develop drugs in order to get their goods to market faster in the biodefense industry.